ANN ARBOR, Mich., Sept. 08, 2017 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company will not renew the equity line with Calm Seas Capital, which expired in June of 2017.
The Company has maintained a financial relationship with Calm Seas Capital since before the creation of its first transgenic silkworm in 2010. After careful consideration of its plan for commercialization and expansion, and after reviewing potential alternatives for financing that expansion, the Company’s management has determined it has outgrown the financial relationship.
In addition to the recently extended U.S. Army contract, the Company implemented several strategic efficiency measures to reduce the Company’s fixed expenses.
“We value Calm Seas Capital’s contributions to many of our accomplishments, including the creation of new transgenics and recombinant fibers, however, given our projections for growth, this is the ideal time to transition for our business model’s next chapters,” said CEO and Founder, Kim Thompson. “As the Company has grown, and, in light of our plans for future expansion and the Army’s recent exercise of its contract option with us for spider silk, it is timely for the Company to explore other avenues that are better aligned with our long term goals. We’ve now grown to the point where we believe we have alternative financing options not previously available.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC (720) 288-8495 [email protected]


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 



